<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00102908</url>
  </required_header>
  <id_info>
    <org_study_id>1R21AI058756-01</org_study_id>
    <secondary_id>1R21AI058756-01</secondary_id>
    <nct_id>NCT00102908</nct_id>
  </id_info>
  <brief_title>Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density</brief_title>
  <official_title>Bisphosphonate Therapy for HIV-Associated Osteopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Bisphosphonates are a type of drug used to prevent and treat bone loss. The purpose of this&#xD;
      study is to determine if zoledronate, an investigational bisphosphonate, can improve bone&#xD;
      mineral density (BMD) in HIV-infected adults.&#xD;
&#xD;
      Study hypothesis: Zoledronate will reduce bone resorption in HIV-infected persons with&#xD;
      osteopenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Decreased BMD and bone loss is estimated to affect up to 67.5% of the HIV-infected&#xD;
      population. HIV-associated bone loss may be a result of antiretroviral treatment (ART), but&#xD;
      can also be caused by the infection itself. To date, treatment for this bone loss has not&#xD;
      been established. Before prescribing drugs to treat bone loss, physicians must take into&#xD;
      account patients' already demanding ART schedules and potential nonadherence. This study will&#xD;
      evaluate the efficacy of a single IV dose of zoledronate, an investigational bisphosphonate,&#xD;
      in treating HIV-associated bone loss.&#xD;
&#xD;
      This study will last 1 year. Participants will be randomly assigned to receive zoledronate or&#xD;
      placebo at study entry; their assigned intervention will be given in a 20- to 30-minute&#xD;
      infusion on an outpatient basis. There will be 7 study visits: at screening, study entry,&#xD;
      Week 2, and Months 3, 6, 9, and 12. Blood collection will occur at all visits. Medical&#xD;
      history, a physical exam, a dual-energy x-ray absorptiometry (DEXA) scan to measure bone&#xD;
      density, and a nutrition evaluation will occur at selected visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone metabolic markers</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety outcomes</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV Infections</condition>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive zoledronate at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive zoledronate placebo at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronate</intervention_name>
    <description>Zoledronate infusion</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronate placebo</intervention_name>
    <description>Zoledronate placebo infusion</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-infected&#xD;
&#xD;
          -  On stable antiretroviral regimen for at least 3 months&#xD;
&#xD;
          -  Able to walk&#xD;
&#xD;
          -  Lumbar spine or total hip BMD T-score at least 1.5 SD and no more than 3.5 SD below&#xD;
             the mean BMD&#xD;
&#xD;
          -  No prevalent fractures at entry OR 1 prevalent vertebral fracture that has been&#xD;
             asymptomatic during the last 2 years prior to study entry&#xD;
&#xD;
          -  HIV viral load of less than 5000 copies/ml within the 2 months prior to study entry&#xD;
&#xD;
          -  CD4 count of more than 100 cells/mm3 within the 2 months prior to study entry&#xD;
&#xD;
          -  Willing to use acceptable forms of contraception during the study period and for 6&#xD;
             months after study completion. Participants who are female and postmenopausal will be&#xD;
             required to take hormone replacement therapy during this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with bisphosphonates or fluoride&#xD;
&#xD;
          -  Use of supraphysiologic systemic estrogen/androgen therapy or corticosteroid therapy&#xD;
             within the 3 months prior to study entry. Participants who have taken hormone&#xD;
             replacement therapy are not excluded.&#xD;
&#xD;
          -  Significant liver or kidney disease&#xD;
&#xD;
          -  Hemoglobin less than 8 g/dL&#xD;
&#xD;
          -  Serum calcium less than 8 mg/dL&#xD;
&#xD;
          -  Laboratory evidence of low levels of estrogens or androgens&#xD;
&#xD;
          -  Laboratory evidence of overactive parathyroid glands&#xD;
&#xD;
          -  History of thyroid, parathyroid, or other endocrinologic disorder known to affect bone&#xD;
&#xD;
          -  Current use of any therapy known to affect bone&#xD;
&#xD;
          -  Current or history of cancer or chemotherapy&#xD;
&#xD;
          -  Current or history of radiotherapy to the jaw&#xD;
&#xD;
          -  Current osteomyelitis of the jaw or ongoing dental infection&#xD;
&#xD;
          -  Recent tooth extraction or major dental procedure within 3 weeks of study entry&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeannie S. Huang, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/OsteonecrosisOsteoporosisOsteopenia_FS_en.pdf</url>
    <description>Click here for more information about osteonecrosis, osteopenia, and osteoporosis</description>
  </link>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>February 4, 2005</study_first_submitted>
  <study_first_submitted_qc>February 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2005</study_first_posted>
  <last_update_submitted>September 25, 2008</last_update_submitted>
  <last_update_submitted_qc>September 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jeannie S. Huang, MD, MPH</name_title>
    <organization>University of California, San Diego</organization>
  </responsible_party>
  <keyword>Bone Metabolism</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 5, 2015</submitted>
    <returned>March 19, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

